# A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

> **NCT03752294** · PHASE1 · WITHDRAWN · sponsor: **University of Rhode Island**

## Conditions studied

- Mild Cognitive Impairment
- Mild Alzheimer's Disease

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Placebo - Cap

## Key facts

- **NCT ID:** NCT03752294
- **Lead sponsor:** University of Rhode Island
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator left institution
- **Last updated:** 2025-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03752294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03752294, "A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03752294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*